Senores Pharmaceuticals Limited (SENORES) fundamentals
Senores Pharmaceuticals Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SENORES (ISIN INE0RB801010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Senores Pharmaceuticals Limited does
Senores Pharmaceuticals Limited is an India-based pharmaceutical company. The Company manufactures products of international quality to cater to the increasing new age demands of the global healthcare industry. The Company's products include Amphetamine Sulfate Tablets USP, 5 mg and 10 mg; Hydroxychloroquine Sulfate Tablets USP, 200 mg; Ketoconazole Tablets USP, 200 mg; Chlorzoxazone Tablets USP, 250 mg; 5Chlorzoxazone Tablets USP, 500 mg; Ketorolac Tromethamine Tablets USP, 10 mg; Diclofenac Potassium Tablets USP, 25 mg; Diclofenac Potassium Tablets USP, 50 mg, and others. It supplies affordable APIs to generic formulations manufacturers. Its product API include Anastrozole, Aripiprazole, Benfotiamine, Clomiphene Citrate, Desloratadine, Desvenlafaxine Succinate, Fluoxetine Hydrochloride, and others. Its domestic portfolio includes Azithromycin for Injection; Meropenem Injection; Ferric Carboxymaltose Injection; Meropenem and Sulbactam for Injection, and others.
Valuation and market data
| Last close | ₹1463.10 |
|---|---|
| Market capitalisation | ₹5,295 crore |
| Enterprise value | ₹5,364 crore |
| P/E (TTM) | 0.00 |
| Price to book | 6.52 |
| Price to sales (TTM) | 7.34 |
| Book value per share | ₹224.43 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Dec 30 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹172 crore | ₹27 crore | ₹20 crore | 0.00 |
| Mar 2025 | ₹61 crore | ₹5 crore | ₹4 crore | 1.02 |
| Mar 2024 | ₹41 crore | ₹2 crore | ₹1 crore | 0.35 |
| Mar 2023 | ₹19 crore | ₹2 crore | ₹1 crore | 1.26 |
| Mar 2022 | ₹14 crore | ₹1 crore | ₹1 crore | 1.24 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 45.8% |
|---|---|
| Foreign institutions (FII) | 6.6% |
| Mutual funds | 6.6% |
| Other domestic institutions | 3.2% |
| Retail and others | 37.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.